Print

LipoScience, Inc. Announces Exclusive License from Cleveland Clinic to Develop Cardiovascular Test Based on Gut Flora Metabolite  
4/19/2012 9:58:36 AM

RALEIGH, N.C.--(BUSINESS WIRE)--LipoScience, Inc., an in vitro diagnostic company advancing patient care by developing high value proprietary clinical diagnostic tests using nuclear magnetic resonance (NMR) technology, announced that it has entered into an exclusive, worldwide licensing agreement with Cleveland Clinic to develop and commercialize a diagnostic test for cardiovascular disease risk based on a gut flora metabolite known as trimethylamine N-oxide (TMAO). The license agreement was entered into in August 2011.